Verrica Pharmaceuticals (VRCA) Return on Capital Employed (2018 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Return on Capital Employed of 51.5% for Q1 2026, up 24408.0% year-over-year from N/an in Q1 2025, and down 16.55% quarter-over-quarter from 44.19% in Q4 2025.
Verrica Pharmaceuticals (VRCA) Return on Capital Employed (2018 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 51.5% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 24408.0% year-over-year to 51.5%; the TTM figure through Mar 2026 stood at 51.5% (up 24408.0% YoY), while the FY2025 annual figure was 35.63%, up 13403.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 51.5%, down from 44.19% in the prior quarter.
- The five-year high for Return on Capital Employed was 38.81% in Q1 2023, with the low at 454.03% in Q4 2024.
- The 5-year median for Return on Capital Employed is 123.52% (2022), against an average of 156.97%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 36314 bps in 2024, then soared 40985 bps in 2025.
- Verrica Pharmaceuticals' Return on Capital Employed stood at 48.98% in 2022, then plunged by 86 bps to 90.89% in 2023, then plunged by 400 bps to 454.03% in 2024, then surged by 90 bps to 44.19% in 2025, then retreated by 17 bps to 51.5% in 2026.
- Business Quant data shows VRCA's Return on Capital Employed at 51.5% in Q1 2026, 44.19% in Q4 2025, and 147.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 7.88% |
| 10 | Verrica Pharmaceuticals | 99.71 Mn | 88.51 Mn | - | -189.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -189.69% |
| Mar 31, 2026 | -51.50% |
| Dec 31, 2025 | -44.19% |
| Sep 30, 2025 | -147.86% |
| Jun 30, 2025 | -339.16% |
| Mar 31, 2025 | -295.58% |
| Dec 31, 2024 | -454.03% |
| Sep 30, 2024 | -362.11% |
| Jun 30, 2024 | -206.76% |
| Mar 31, 2024 | -141.55% |
| Dec 31, 2023 | -90.89% |
| Sep 30, 2023 | -71.50% |
| Jun 30, 2023 | -39.32% |
| Mar 31, 2023 | -38.81% |
| Dec 31, 2022 | -48.98% |
| Sep 30, 2022 | -44.26% |
| Jun 30, 2022 | -168.55% |
| Mar 31, 2022 | -123.52% |
| Dec 31, 2021 | -80.52% |
| Sep 30, 2021 | -72.54% |